AU4250697A - Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection - Google Patents

Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection

Info

Publication number
AU4250697A
AU4250697A AU42506/97A AU4250697A AU4250697A AU 4250697 A AU4250697 A AU 4250697A AU 42506/97 A AU42506/97 A AU 42506/97A AU 4250697 A AU4250697 A AU 4250697A AU 4250697 A AU4250697 A AU 4250697A
Authority
AU
Australia
Prior art keywords
pkc
medicament
inhibitors
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42506/97A
Inventor
Michael R. Jirousek
Lawrence E. Stramm
Douglas K. Ways
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU4250697A publication Critical patent/AU4250697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU42506/97A 1996-08-30 1997-08-28 Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection Abandoned AU4250697A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2486996P 1996-08-30 1996-08-30
US60024869 1996-08-30
US08917362 1997-08-26
PCT/US1997/015583 WO1998008510A1 (en) 1996-08-30 1997-08-28 Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection

Publications (1)

Publication Number Publication Date
AU4250697A true AU4250697A (en) 1998-03-19

Family

ID=21822790

Family Applications (2)

Application Number Title Priority Date Filing Date
AU42506/97A Abandoned AU4250697A (en) 1996-08-30 1997-08-28 Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
AU42418/97A Abandoned AU4241897A (en) 1996-08-30 1997-08-29 Cement reinforced inflatable seal for a junction of a multilateral

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU42418/97A Abandoned AU4241897A (en) 1996-08-30 1997-08-29 Cement reinforced inflatable seal for a junction of a multilateral

Country Status (2)

Country Link
AU (2) AU4250697A (en)
WO (1) WO1998008510A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548269B1 (en) 1995-11-27 2003-04-15 Millennium Pharmaceuticals, Inc. Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
EP0703917A1 (en) * 1993-06-17 1996-04-03 Novartis AG Indolocarbazole compound useful as proteinkinase c inhibitor
EP0657458B1 (en) * 1993-12-07 2001-08-22 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
AU4241897A (en) 1998-03-19
WO1998008510A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
AU5263496A (en) Targeted catheter drug administration
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
AU6491196A (en) Epidural administration of therapeutic compounds with sustained rate of release
AU3560495A (en) Medicament inhaler
WO2002030409A8 (en) Methods for the treatment of a traumatic central nervous system injury
AU5945296A (en) Medicament for nasal administration
AU7973994A (en) Combination therapy for hiv infection
AU4133400A (en) Cystic fibrosis medicaments
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
AU2787495A (en) Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU6369396A (en) Drug for ameliorating brain diseases
HRP960045B1 (en) Combination therapy for hiv infection
AU7982098A (en) Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis
AU4179497A (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment f AIDS
AU4250697A (en) Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
AU3071999A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
IL128494A0 (en) Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
AU3071799A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
AU2462097A (en) The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain
HU9603567D0 (en) Combination therapy for hiv infection
AU665052B2 (en) The use of a compound for the manufacture of a medicament for the treatment of HIV infection
AU6702596A (en) Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted